SGP Stock Forecast: SpyGlass Pharma, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering SpyGlass Pharma, Inc. hold a median 12-month price target of $42 — +85.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
SGP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores SpyGlass Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (48): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own SpyGlass Pharma, Inc. — and when they’d sell — is the membership.
SGP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SGP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +85.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | $37 |
| 3 Mar 2026 | Citigroup | Initiates | Buy | $42 |
| 3 Mar 2026 | Jefferies | Initiates | Buy | $62 |
| 3 Mar 2026 | Leerink Partners | Initiates | Outperform | $42 |
| 3 Mar 2026 | Stifel | Initiates | Buy | $42 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SGP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
SpyGlass Pharma, Inc. (SGP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −18.1×
- Price / sales
- —
- Price / book
- 3.0×
- EV / EBITDA
- −10.4×
Cheaper than 96% of US stocks
Cheaper than 33% of US stocks
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 40.3%
- Return on assets
- −34.4%
- Dividend yield
- —
Higher than 92% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SGP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGP appears on the weeks it earns a place.
Frequently asked questions about SGP stock
What is the SGP stock price forecast for 2026-2027?
The 5 Wall Street analysts covering SpyGlass Pharma, Inc. have a median 12-month price target of $42, with estimates ranging from $37 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SGP stock a buy right now?
Of the 5 analysts covering SpyGlass Pharma, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SpyGlass Pharma, Inc. 2 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SGP?
As at 1 Aug 2026, SpyGlass Pharma, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (48 of 100).
Will SGP stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +85.2% from the last close, and Ticker Nerd's factor model ranks SpyGlass Pharma, Inc. 2 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SGP stock forecast for 2030?
No analyst covering SpyGlass Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $62 over the next 12 months.
What does SpyGlass Pharma, Inc. do?
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company specializing in sustained drug delivery solutions for chronic eye conditions, particularly open-angle glaucoma and ocular hypertension.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company specializing in sustained drug delivery solutions for chronic eye conditions, particularly open-angle glaucoma and ocular hypertension. Founded in 2019 by Malik Y. Kahook, M.D., and Glenn Sussman, the company develops innovative platforms that integrate approved medicines like bimatoprost into familiar surgical procedures to provide long-term disease control and vision preservation. Its lead candidate, the BIM-IOL System, combines proprietary drug pads with intraocular lenses for implantation during routine cataract surgery, delivering therapy over three years and addressing treatment gaps in daily eye drops. Additionally, the BIM-DRS targets glaucoma patients not undergoing cataract surgery. Headquartered in Aliso Viejo, California, SpyGlass Pharma employs 65 professionals and is led by CEO Patrick Mooney, with a team boasting deep expertise in ophthalmology, drug delivery, and clinical development. The company's non-bioerodible SpyGlass Platform originated from the University of Colorado Anschutz School of Medicine, positioning it to transform ophthalmic care by reducing patient burden and enhancing outcomes in the healthcare sector.
CEO Mr. Patrick H. Mooney · 68 employees · United States · https://www.spyglasspharma.com